Many Seniors at Risk for Financial Precarity From Cost of Hospital Stay
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
TUESDAY, Oct. 29, 2024 -- Many Medicare beneficiaries are at risk for financial hardship from the costs of a single hospital stay, according to a study published online Oct. 29 in the Annals of Internal Medicine.
Paula Chatterjee, M.D., M.P.H., from the University of Pennsylvania Perelman School of Medicine, and colleagues identified beneficiaries who would face financial precarity if exposed to the Medicare Part A hospital deductible ($1,600) in a cross-sectional study of the 2018 wave of the Health and Retirement Study. Estimates of financial precarity, defined as having insufficient funds to pay the deductible, were examined across four scenarios.
The researchers found that 45.0 percent of the 4,881 beneficiaries had insufficient funds in checking and savings accounts to pay the Medicare hospital deductible. The prevalence of financial precarity was higher for Black and Hispanic versus White beneficiaries (73.5 and 76.2 percent, respectively, versus 36.2 percent), for those with less versus more than high school education (70.0 versus 37.1 percent), and for those with three or more versus two or fewer chronic conditions (49.2 versus 39.1 percent). Overall, 50.7 percent were financially precarious when financial precarity was defined to include beneficiaries with insufficient liquid assets to pay the deductible while maintaining a $5,000 reserve for future living expenses. Thirty-nine percent remained financially precarious building off this definition to assume supplemental insurance covered the deductible.
"Broadening financial protections in Medicare to beneficiaries with moderate incomes and limited assets may achieve greater economic parity and equity among older adults by increasing assistance to those with limited savings and gaps in supplemental insurance," the authors write.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2024-10-30 12:00
Read more
- FDA Approves Revuforj (revumenib) for the Treatment of Adult and Pediatric Patients with Relapsed or Refractory Acute Leukemia with a KMT2A Translocation
- Bird Flu Infects 1 in 14 Dairy Workers Exposed; CDC Urges Better Protections
- AskBio Receives FDA Rare Pediatric Disease and Orphan-Drug Designations for AB-1003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2I/R9
- NIH Trial of Rectal Microbicide for HIV Prevention Begins in the United States
- FDA Approves Danziten (nilotinib) Tablets, the First and Only Nilotinib With No Mealtime Restrictions
- At-Home Brain Stimulation Treatment Can Safely Ease Depression
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions